Justia Patents Opinion Summaries

Articles Posted in International Trade
by
Promega sublicensed a patent, which claims a toolkit for genetic testing, to Life Technologies for the manufacture and sale of kits for use in licensed law enforcement fields worldwide. One of the kit’s five components, an enzyme, was manufactured by Life Technologies in the U.S. and shipped to the United Kingdom, where the other components were made, for combination there. When Life Technologies began selling kits outside the licensed fields of use, Promega sued, citing section 271(f)(1) of the Patent Act, which prohibits the supply from the U.S. of “all or a substantial portion of the components of a patented invention” for combination abroad. The district court held that the section did not encompass the supply of a single component of a multicomponent invention. The Federal Circuit reversed, reasoning that a single important component could constitute a “substantial portion” of the components of an invention. The Supreme Court reversed. The supply of a single component of a multicomponent invention for manufacture abroad does not give rise to liability under section 271(f)(1), which refers to a quantitative measurement. The Court rejected Promega’s proffered “case-specific approach,” which would require a factfinder to decipher whether the components at issue are a “substantial portion” under either a qualitative or a quantitative test. When a product is made abroad and all components but a single commodity article are supplied from abroad, the activity is outside the statute’s scope. View "Life Technologies Corp. v. Promega Corp." on Justia Law

by
The International Trade Commission investigated DeLorme for violating the Tariff Act, 19 U.S.C. 1337, by importing, selling for importation, or selling after importation “two-way global satellite communication devices, system and components thereof” that allegedly infringed BriarTek’s patent, directed to emergency monitoring and reporting systems comprising a user unit and a monitoring system that communicate through a satellite network. The accused products included DeLorme’s InReach satellite-communication devices and software used with the devices. The Commission terminated the investigation based on entry of a consent order, in which DeLorme agreed not to import, sell for importation, or sell or offer for sale within the U.S. after importation any two-way global satellite communication devices, system, and components thereof, that infringe the Patent until the expiration, invalidation, or unenforceability of the Patent. In 2013, the Commission instituted an enforcement proceeding based on BriarTek’s allegations that DeLorme sold InReach devices containing imported components. DeLorme sought declaratory judgment of noninfringement and invalidity of the patent. While DeLorme’s action was pending, the Commission found that DeLorme violated the Order and imposed a civil penalty of $6,242,500. The Federal Circuit affirmed, rejecting an argument that the Consent Order instead prohibited DeLorme from using imported components only if the components themselves infringed the patent. View "DeLorme Publ'g Co., Inc. v. Int'l Trade Comm'n" on Justia Law

by
The Tariff Act of 1930 gives the International Trade Commission authority to remedy only those unfair acts that involve the importation of “articles” as described in 19 U.S.C. 1337(a). The Commission instituted an investigation based on a complaint filed by Align, concerning violation of 19 U.S.C. 1337 by reason of infringement of various claims of seven different patents concerning orthodontic devices. The accused “articles” were the transmission of the “digital models, digital data and treatment plans, expressed as digital data sets, which are virtual three-dimensional models of the desired positions of the patients’ teeth at various stages of orthodontic treatment” from Pakistan to the United States. The Federal Circuit reversed, holding that the Commission lacked jurisdiction. The Commission’s decision to expand the scope of its jurisdiction to include electronic transmissions of digital data runs counter to the “unambiguously expressed intent of Congress.” View "ClearCorrect Operating, LLC v. Int'l Trade Comm'n" on Justia Law

by
Cross Match claimed that defendants violated 19 U.S.C. 1337(a)(1)(B)(i) by importing articles that infringe or are used to infringe its patents. The International Trade Commission entered a limited exclusion order barring importation of certain optical scanning devices. In 2013, the Federal Circuit first vacated and remanded for revision of the order to bar only a subset of the scanners, reasoning that an exclusion order may not be predicated on a theory of induced infringement under 35 U.S.C. 271(b) where direct infringement does not occur until after importation of the articles the exclusion order would bar. In doing so, the panel effectively eliminated trade relief under Section 337 for induced infringement and potentially for all types of infringement of method claims. The Federal Circuit later granted en banc rehearing and upheld the Commission’s position. Because Section 337 does not answer the question, the Commission’s interpretation of Section 337 is entitled to Chevron deference. The Commission’s interpretation is reasonable because it is consistent with Section 337 and Congress’ mandate to the Commission to safeguard United States commercial interests at the border. View "Suprema, Inc. v. Int'l Trade Comm'n" on Justia Law

by
Celgard is a developer and manufacturer of battery membranes, used to separate chemical cell components in lithium-ion batteries, preventing contact between the positive and negative electrodes. The patents concerns a separator technology that uses a ceramic composite coating that helps prevent electrical shorting. This technology is used in rechargeable batteries in electronic vehicles and consumer electronic devices such as laptops and cellular phones. Celgard is headquartered in Charlotte, North Carolina. SKI is a manufacturer of separators for use in lithium-ion batteries. SKI mainly supplies the separators to third-party manufacturers, but also manufactures batteries that include the separators it produces. SKI’s principal place of business is in Seoul, Korea. All of SKI’s design, manufacturing, and sales operations are based in Korea. Celgard sued SKI for infringement. Celgard sought to establish the district court’s jurisdiction based on allegations that SKI purposefully directed activities at the forum state through sales and offers for sale of its accused separators to residents of North Carolina. The Federal Circuit affirmed dismissal for lack of personal jurisdiction, under either a purposeful-direction theory or a stream-of-commerce theory, noting an absence of evidence that SKI ever sold or offered for sale the accused products in North Carolina. View "Celgard, LLC v. SK Innovation Co., Ltd." on Justia Law

by
Standard markets kinesiotherapy devices, including models that practice claims of its 605 Patent. In 2009, Standard formed a subsidiary to distribute products in the U.S. Neither Standard nor Standard U.S. manufactures in the U.S.; Standard sources components from suppliers in the U.S. and other countries. It contracts Chinese manufacturers to assemble devices from those components for export to more than 50 countries, including the U.S. The U.S. International Trade Commission (ITC) addressed four components in its domestic industry analysis: a backbone material, a rubber, microcontrollers, and a pigment. The backbone material, rubber, pigment, and wafers used in the microcontrollers are manufactured in the U.S. Lelo, a California corporation with a Swedish majority shareholder, imports kinesiotherapy devices. Standard filed a 19 U.S.C. 1337 complaint alleging that Lelo imported kinesiotherapy devices and components that infringed its 605 Patent. The ITC concluded that statutory domestic industry requirements were satisfied upon a showing of a “significant investment in plant or equipment” and a “significant employment of labor or capital.” The Eighth Circuit reversed, holding that qualitative factors alone are insufficient. The purchase of so-called “crucial” components from third-party U.S. suppliers was insufficient to satisfy the “significant investment” or “significant employment of labor or capital” criteria absent evidence that connects the cost of the components to an increase of U.S. investment or employment. View "LELO Inc. v. Int'l Trade Comm'n" on Justia Law

by
Licensees entered into a licensing agreement with Safeblood Tech for the exclusive rights to market patented technology overseas. After learning that they could not register the patents in other countries, Licensees sued Safeblood for breach of contract and sued Safeblood, its officers, and patent inventor for fraud, constructive fraud, and violations of the Arkansas Deceptive Trade Practices Act (ADTPA), Ark. Code 4-88-101 to -115. The district court dismissed the fraud claims at summary judgment. The remaining claims proceeded to trial and a jury found for Licensees, awarding them $786,000 in contract damages and no damages for violations of the ADTPA. The district court awarded Licensees $144,150.40 in prejudgment interest. The Eighth Circuit reversed as to the common-law fraud claim and the award of prejudgment interest, but otherwise affirmed. Licensees produced sufficient evidence that the inventor made a false statement of fact; the district court did not abuse its discretion when it gave the jury a diminution-in-product-value instruction; and Licensees waived their inconsistent-verdict argument. View "Yazdianpour v. Safeblood Techs., Inc." on Justia Law

by
uPI and Richtek design and sell DC-DC controllers that convert direct current from one voltage to another, and are embodied in chips for downstream devices such as computer motherboards. uPI was founded by former Richtek employees; its chips are imported into the U.S. either directly or as incorporated in downstream devices. Richtek complained to the International Trade Commission that uPI misappropriated Richtek’s trade secrets and infringed Richtek’s U.S. patents, in violation of the Tariff Act, 19 U.S.C. 1337. uPI offered to enter into a consent order and to cease importation of products produced using or containing Richtek’s trade secrets or infringing Richtek’s patents. Over Richtek’s objection, the ALJ entered the consent order substantially as drafted by uPI. The Commission terminated the investigation. A year later Richtek filed an Enforcement Complaint. An ALJ distinguished between products that were accused in the prior investigation and products allegedly developed and produced after entry of the Consent Order, finding violations as to the formerly accused products and that the post- Consent Order products infringed two patents, but were independently developed and not produced using Richtek’s trade secrets. The Commission affirmed with respect to the formerly accused products and reversed in part with respect to the post-Order products. The Federal Circuit affirmed concerning the formerly accused products, but reversed the ruling of no violation as to the post-Consent Order products.View "UPI Semiconductor Corp. v. Int'l Trade Comm'n" on Justia Law

by
Align’s Invisalign System, an alternative to conventional braces, uses a series of clear dental aligners that are worn sequentially over time to adjust the position of a patient’s teeth. The aligners must be custom-designed for the patient’s unique teeth. Align’s asserted patents are directed to methods and treatment plans using digital data sets. In 2005, Align’s founder and former CEO founded OrthoClear and used former Align employees to manufacture dental aligners. Align filed a complaint with the International Trade Commission, alleging that OrthoClear violated 19 U.S.C. 1337 by importing, selling for importation, or selling within the U.S., aligners that infringe Align’s patents, and by misappropriating Align’s trade secrets. A 2006 settlement required OrthoClear to assign its entire intellectual property portfolio to Align. The Commission entered the Consent Order and terminated the investigation. Suspecting that OrthoClear and others were violating the Consent Order, Align sought an enforcement proceeding. Rather than issuing an “initial determination,” the ALJ issued an order, denied a motion to terminate and scheduled a trial. The Commission concluded that the order constituted an “initial determination,” subject to its review, reversed, and terminated the enforcement proceeding, finding that the accused digital data sets were not covered by the scope of the consent order. The Federal Circuit vacated, finding that the Commission erred in reviewing the order. View "Align Tech., Inc. v. Int'l Trade Comm'n" on Justia Law

by
Nooren owns patent 044, entitled “Use of a Preparation for Insulation/Sealing and Coating Purposes and Method for Sealing Manhole Covers,” which discloses a composition for insulating and protecting substrates, such as manhole covers, underground tanks, pipes, and cable sleeves, from corrosion, water ingress, and mechanical stresses. The patent is licensed exclusively to Stopaq, a Dutch company that designs and manufactures coatings and sealants that exhibit both viscous and elastic properties (visco-elasticity) and are designed for corrosion protection and waterproofing. Kleiss, a Dutch company, manufactures similar products that prevent corrosion and protect against leaks, which are distributed in the U.S. by Amcorr. Kleiss and Amcorr sought a declaratory judgment in the Netherlands that their products did not infringe the 044 patent. Nooren filed suit in the U.S., alleging infringement. The parties agreed to focus on the phrase “a filler comprising a plurality of fractions each comprising different size particles, and wherein said different fractions have different particle size distributions” in the only independent claim in the patent. The court granted summary judgment of noninfringement in favor of Amcorr. The Federal Circuit vacated, holding that the district court erred in at least on claim construction. View "Frans Nooren Afdichtingssystem v. Stopaq Amcorr Inc." on Justia Law